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The study sample comprised 240 patients, 120 in each group. The mean age of the patients in the traditional pharmacokinetic dosing group was 47 (+/-16) years, and 76 were men. The mean age of the patients in the NM dosing group was 49.2 (+/-16.8) years, and 78 were men. No power calculations were reported. All patient treated in the respective study periods were considered for inclusion in the study.
Study design
This was a case-control study carried out in a single centre. No randomisation was carried out. The study compared two groups of patients treated by traditional and NM dosing approaches, respectively. The average length of therapy was 8.6 (+/-7.2) days for the pharmacokinetic group and 9.9 (+/-9.4) days for the NM group. No loss to follow-up was reported.
For the NM patients, if the vancomycin were to be continued after day 5, blood to determine a single trough concentration was drawn on day 5. If the trough concentration was within the range 5 to 20 microg/mL, no change in therapy was made. If the trough concentration was below 5 microg/mL, the dosing interval was decreased to the next standard interval. If the trough concentration was above 20 microg/mL, either the dose was cut by 50% (i.e. 1,000 microg decreased to 500 microg) or the dosing interval was increased to the next standard interval (i.e. from 6 to 8 hours or from 12 to 24 hours). In cases where an adjustment was made, the trough concentration was measured again after 3 days.
Analysis of effectiveness
The clinical outcomes were: cure, i.e. complete resolution of all the signs and symptoms of infection; improvement, i.e. the resolution of or lack of progression in most signs and symptoms; failure, such as the persistence or progression of all signs and symptoms after 5 days' therapy, death due to infection, and/or the inability to complete vancomycin therapy due to adverse effects; or indeterminate, i.e. extenuating circumstances precluding classification as either cure or failure.
The average number of days taken to eradicate the organism was also assessed.
Nephrotoxicity was defined as an increase in serum creatinine of 0.5 mg/dL or 50%, whichever was greater, on two consecutive occasions during vancomycin therapy. The occurrence of cases of ototoxicity was also assessed. The microbiologic outcomes were classified as cure, failure, or indeterminate.
Cure was defined as at least one of the following: elimination of the original causative organism(s) from the same site, absence of appropriate material for culture (i.e. sputum), or the repeated aspiration of fluid was not clinically justified).
Failure or persistence was defined as the failure to eradicate the original causative organism(s) from the same site.
Indeterminate was defined as at least one of the following: no evaluation because of death, withdrawal from vancomycin before the follow-up cultures could be obtained, and incomplete microbiological data.
Finally, NM was validated using those patients dosed by NM who had trough concentrations measured on the specified dosing regimen. The patient samples were comparable in terms of their age, gender, underlying disease states (diabetes, cancer, HIV, burns), the length of therapy, the number of days in the intensive care unit, and concomitant nephrotoxic agents.
Effectiveness results
No difference was found between the pharmacokinetic and NM groups for the clinical outcomes. For the pharmacokinetic group, the rate of cure was 45%, the rate of improvement was 35%, the rate of failure was 13.3%, and the rate of indeterminate was 6.7%. The corresponding rates for the NM group were 44.3% (cure), 39.6%
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The microbiological response was assessed for 56 patients in the pharmacokinetic group and 37 patients in the NM group. No statistically significant differences were found between the two groups. For the pharmacokinetic group, the rate of cure was 46.4%, the rate of failure or persistence was 26.8%, and the rate of indeterminate was 26.8%. The corresponding rates for the NM group were 37.8% (cure), 29.7% (failure or persistence) and 32.4% (indeterminate).
The average number of days to eradicate the organism was 3.2 (+/-3.2) in the pharmacokinetic group and 4.4 (+/-5.3) in the NM group, (P=0.3).
There was no difference in overall nephrotoxicity when assessing all other concomitant nephrotoxins. For patients who received vancomycin alone, a higher but not statistically significant difference in the rate of nephrotoxicity was observed in the NM group, compared with the pharmacokinetic group. The rate of nephrotoxicity was 8.6% (3 out of 35) in the NM group and 3.1% (1 out of 32) in the pharmacokinetic group. The therapy was not discontinued in any patient, and the renal function returned to baseline before discharge from the hospital. No cases of ototoxicity were observed.
Of the 77 patients who were included in the validation of NM, 72 patients (94%) had a trough concentration in the target range. The NM was most reliable in patients with a Clcr above 90 mL/minute.
